ECSP21010874A - Piridopirimidinas como inhibidores del receptor de histamina h4 - Google Patents

Piridopirimidinas como inhibidores del receptor de histamina h4

Info

Publication number
ECSP21010874A
ECSP21010874A ECSENADI202110874A ECDI202110874A ECSP21010874A EC SP21010874 A ECSP21010874 A EC SP21010874A EC SENADI202110874 A ECSENADI202110874 A EC SENADI202110874A EC DI202110874 A ECDI202110874 A EC DI202110874A EC SP21010874 A ECSP21010874 A EC SP21010874A
Authority
EC
Ecuador
Prior art keywords
histamine
pyridopyrimidines
receptor inhibitors
receptor
solvates
Prior art date
Application number
ECSENADI202110874A
Other languages
English (en)
Inventor
Pedro Bárbara Noverges
Vivar Reyes Corcóstegui
Herrero Gonzalo Hernández
Arce Arturo Zazpe
Domínguez Neftalí García
Cerdeiras Paloma Tato
Tizne Roberto Olivera
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of ECSP21010874A publication Critical patent/ECSP21010874A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de fórmula (I) o a sales o solvatos farmacéuticamente aceptables de los mismos, a composiciones farmacéuticas que los comprenden y a su uso en el tratamiento y/o la prevención de enfermedades o trastornos mediados por el receptor de histamina H4.
ECSENADI202110874A 2018-07-25 2021-02-17 Piridopirimidinas como inhibidores del receptor de histamina h4 ECSP21010874A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382559 2018-07-25

Publications (1)

Publication Number Publication Date
ECSP21010874A true ECSP21010874A (es) 2021-03-31

Family

ID=63207688

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202110874A ECSP21010874A (es) 2018-07-25 2021-02-17 Piridopirimidinas como inhibidores del receptor de histamina h4

Country Status (27)

Country Link
US (1) US20210300922A1 (es)
EP (1) EP3827005B1 (es)
JP (1) JP7093462B2 (es)
KR (1) KR102603203B1 (es)
CN (1) CN112739699B (es)
AU (1) AU2019310889B2 (es)
BR (1) BR112021001270A2 (es)
CA (1) CA3107556C (es)
CL (1) CL2021000184A1 (es)
CO (1) CO2021001925A2 (es)
DK (1) DK3827005T3 (es)
EA (1) EA202190339A1 (es)
EC (1) ECSP21010874A (es)
ES (1) ES2929227T3 (es)
HR (1) HRP20221250T1 (es)
HU (1) HUE059824T2 (es)
LT (1) LT3827005T (es)
MA (1) MA53372B1 (es)
MX (1) MX2021000966A (es)
PE (1) PE20211638A1 (es)
PH (1) PH12021550143A1 (es)
PL (1) PL3827005T3 (es)
PT (1) PT3827005T (es)
RS (1) RS63661B1 (es)
SG (1) SG11202100575QA (es)
WO (1) WO2020020939A1 (es)
ZA (1) ZA202101092B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56020A (fr) * 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés de pyridopyrimidines utilisés en tant qu'inhibiteurs de p2x3
JP2023084709A (ja) * 2020-04-28 2023-06-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ヒスタミンｈ４受容体調節作用を有する新規二環化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789399A1 (en) 2004-08-31 2007-05-30 AstraZeneca AB Quinazolinone derivatives and their use as b-raf inhibitors
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
CA2737217A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
EP2270002A1 (en) 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
JP6535430B2 (ja) * 2012-09-28 2019-06-26 イグニタ、インク． 非定型プロテインキナーゼｃのアザキナゾリン阻害薬

Also Published As

Publication number Publication date
KR20210038909A (ko) 2021-04-08
BR112021001270A2 (pt) 2021-04-20
MA53372B1 (fr) 2022-10-31
EP3827005A1 (en) 2021-06-02
PL3827005T3 (pl) 2022-11-28
AU2019310889A1 (en) 2021-03-11
DK3827005T3 (da) 2022-09-19
WO2020020939A1 (en) 2020-01-30
PH12021550143A1 (en) 2021-09-13
JP2021531304A (ja) 2021-11-18
CN112739699B (zh) 2023-11-28
AU2019310889B2 (en) 2022-03-31
LT3827005T (lt) 2022-11-10
ES2929227T3 (es) 2022-11-25
EP3827005B1 (en) 2022-08-17
CN112739699A (zh) 2021-04-30
US20210300922A1 (en) 2021-09-30
CA3107556A1 (en) 2020-01-30
NZ773053A (en) 2023-10-27
SG11202100575QA (en) 2021-02-25
PE20211638A1 (es) 2021-08-24
CL2021000184A1 (es) 2021-07-09
MA53372A (fr) 2021-06-02
RS63661B1 (sr) 2022-11-30
MX2021000966A (es) 2021-07-06
HRP20221250T1 (hr) 2022-12-09
ZA202101092B (en) 2022-09-28
PT3827005T (pt) 2022-11-04
HUE059824T2 (hu) 2023-01-28
CA3107556C (en) 2022-10-25
EA202190339A1 (ru) 2021-05-20
CO2021001925A2 (es) 2021-03-08
JP7093462B2 (ja) 2022-06-29
KR102603203B1 (ko) 2023-11-16

Similar Documents

Publication Publication Date Title
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2021000329A1 (es) Compuestos útiles en terapia del vih
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
UY36608A (es) Derivados de indol
DOP2017000138A (es) Derivados de fumagilol
AR123685A1 (es) Antagonistas del mrgx2